Evidence map›Paper›PMID 39564150›Full record

ArticleOpen forum infectious diseases2024

Understanding Typology of Preexposure Prophylaxis (PrEP) Persistence Trajectories Among Male PrEP Users in the United States.

Yi-No Chen, Junlan Zhou, Heather S Kirkham, Edward A Witt, Samuel M Jenness, Kristin M Wall, Rishi Kamaleswaran, Ashley I Naimi, Aaron J Siegler

Abstract read
In one paragraph

Article in Open forum infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yi-No ChenDepartment of Epidemiology, Emory University, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0002-8459-7881
Junlan ZhouHealth Analytics, Research, and Reporting Department, Walgreen Co., Deerfield, Illinois, USA.
Heather S KirkhamHealth Analytics, Research, and Reporting Department, Walgreen Co., Deerfield, Illinois, USA.ORCID https://orcid.org/0000-0003-1247-1005
Edward A WittHealth Analytics, Research, and Reporting Department, Walgreen Co., Deerfield, Illinois, USA.ORCID https://orcid.org/0009-0006-4968-4652
Samuel M JennessDepartment of Epidemiology, Emory University, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0001-8840-105X
Kristin M WallDepartment of Epidemiology, Emory University, Atlanta, Georgia, USA.
Rishi KamaleswaranDepartment of Biomedical Informatics, Emory University, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0001-8366-4811
Ashley I NaimiDepartment of Epidemiology, Emory University, Atlanta, Georgia, USA.
Aaron J SieglerDepartment of Epidemiology, Emory University, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0002-1510-8175

Funding

Making it last: A randomized, controlled trial of a home care system to promote persistence in PrEP careR01MH114692 · NIMH · EMORY UNIVERSITY · PI MAYER, KENNETH H, SIEGLER, AARON JULIUS · 2017 to 2021
$5.8M
STI Response and Recommendations Under PrEP (STIRRUP)R01MH128130 · NIMH · EMORY UNIVERSITY · PI Samuel Jenness · 2022 to 2026
$3.1M
Establishing PREMISE: A PrEP Epidemiology, Modeling, and Surveillance SystemR01AI181799 · NIAID · EMORY UNIVERSITY · PI Aaron Julius Siegler, Patrick Sean Sullivan · 2024 to 2026
$3.0M
NIAID NIH HHS R01 AI181799NIMH NIH HHS R01 MH114692NIMH NIH HHS R01 MH128130
6 · The paper itself

Abstract

Introduction: Understanding longitudinal patterns of preexposure prophylaxis (PrEP) use among men who have sex with men could offer insights for developing efficient and timely interventions to promote PrEP persistence. Setting: We extracted 2 years of pharmacy fill records for 4000 males who initiated PrEP in 2017 at a national chain pharmacy in the United States. Methods: Group-based trajectory models were used to develop PrEP trajectory clusters, with periods of use defined based on optimal PrEP seroprotection probabilities (ie, PrEP use frequency ≥4 doses/week). Multinomial logistic regressions were used to evaluate the associations between sociodemographic covariates and identified trajectory group membership. Results: We identified 4 distinct groups of PrEP persistence trajectories: (1) persistent use of PrEP throughout the period (persistent user), (2) brief use followed by sustained cessation of PrEP use (brief user), (3) PrEP use up to the mid-term followed by sustained cessation of PrEP use (mid-term user), and (4) PrEP use, followed by cessation and subsequent reinitiation (PrEP reinitiator). Persistent users and brief users accounted for 40.1% and 22.9% of the population, respectively, whereas mid-term users and reinitiators accounted for 18.9% and 18.2%, respectively. Older age at PrEP initiation, commercial insurance as the primary payer of PrEP, and use of specialty pharmacy were found to be associated with persistent PrEP use over the other patterns of nonpersistence. Conclusions: Subgroups of PrEP users could benefit from PrEP persistence interventions that target specific timings of likely PrEP cessation or considerations of reinitiation.

Indexed as

Group-based trajectory modelHIV preventionMedication adherenceMSMPrEP persistence

Identifiers

PMID39564150
PMCPMC11574613

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.